Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hunter-Fleming Ltd.

Division of Newron Pharmaceuticals SPA

Latest From Hunter-Fleming Ltd.

Alzheimer's R&D: Tweaking Venture's Risk-Reward Ratio

Building Alzheimer's-focused companies remains difficult, in part because venture capital remains scarce. But advancese in diagnostic and imaging tools, improved means of measuring the impact of drugs on cognition, and a better understanding of therapeutic targets mean investment risks are improving, say some executives and VCs. Can Alzheimer's attract more mainstream VC investment and pay off with more lucrative deals like Pfizer's acquisition of Rinat?
Strategy Business Strategies

Asset-Focused Funding

A handful of early-stage VCs think they can generate better returns building and selling individual products, rather than companies.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Inflammation
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Newron Pharmaceuticals SPA
  • Senior Management
  • Mike Capaldi, PhD, CEO
    Neil Hockaday, CFO
    Bruce Holman, PhD, Dir., Bus. Dev.
  • Contact Info
  • Hunter-Fleming Ltd.
    Phone: (44) 0117 900 8265
    Regus House
    1 Friary
    Temple Quay, BS1 6EA